AstraZeneca promises sales increases, later

Written by Joseph Nordqvist

Published: 11:39, May 6, 2014

AstraZeneca promises sales increases to more than $45 billion within the next nine years as exciting new medications come onto the market, compared to $25.7 billion last year. However, the company added that before tomorrow’s jam, there may be a short-term decline in sales.

After Pfizer reported a 15% fall in profits for Q1 2014, its $106 billion bid for AstraZeneca is beginning to sound rather hollow.

While AstraZeneca has an impressive range of experimental drugs in the pipeline, Pfizer is facing a growing number of key drugs near the end of their patent life and very few new products. If this were a game of Monopoly, AstraZeneca has the hotels and train stations while Pfizer is just full of cash– and we all know who eventually wins in that game.

Be patient, AstraZeneca asks shareholders

AstraZeneca urged its shareholders to be patient, warning that a Pfizer deal could deprive them of huge gains later on.

Leif Johansson, Chairman of AstraZeneca, said:

“The increasingly visible success of our independent strategy highlights the future prospects for our shareholders. These are benefits that should fully accrue to AstraZeneca’s shareholders.”

While accepting that AstraZeneca (AZ), the UK’s second largest pharmaceutical company, has an impressive portfolio of experimental drugs in some major medical areas, analysts and investors still argue as to their commercial future.

Pfizer keen on AstraZeneca takeover

Pfizer has approached AZ twice this year, once in January and again at the end of April. Just last week it increased its offer, but AZ has stood its ground, saying the £50 per share bid was nowhere near enough.

While AZ may not appear keen on a Pfizer merger or takeover, several media sources have quoted people familiar with the negotiations who say it may become interested if a new offer acknowledged the true value of the company.

AZ, like Pfizer, is also facing patient expiries on key products, hence a warning of falling sales before the surge later on.

AZ says that from 2017 onward there will be “strong and consistent growth” when new drugs for heart disease, diabetes, cancer, Alzheimer’s and respiratory disorders come onto the market.

A strategy for Pfizer to put up more or shut up?

Jonathan Guthrie writes in the Financial Times that making predictions about ten years’ time is a safe thing to do, because by then nobody will remember what you said. He believes AstraZeneca’s announcement today is aimed at Pfizer rather than its shareholders.

Guthrie writes:

“So publication by the UK drug company of internal sales estimates are best interpreted as an artefact of its battle to make would-be acquirer Pfizer offer more money or sling its hook.”

For Pfizer, AstraZeneca’s immediate appeal is the UK’s 21% corporate tax compared to 35% in the US. Moving its headquarters to London could save the world’s largest drugmaker over $1 billion annually in tax. Add to this the write-offs in US accruals.

A growing number of American companies are looking to buy foreign firms based in countries with lower corporate tax rates, such as the UK or Ireland. The US currently has the highest rate of corporate tax among the advanced economies.

Joseph Nordqvist Avatar

Other News

How a business handles customer data can shape its relationship with buyers

Nov 16, 2026

Trying a customized product can shape what shoppers choose later

Nov 16, 2026

Why the way unit prices are shown can change how shoppers judge a deal

Nov 16, 2026

Why the weather can affect ratings of cold-weather gear

Nov 15, 2026

Seeing a purchase as part of a collection can change the shopping experience

Nov 15, 2026

Retail app ads may influence what customers do after installation

Nov 15, 2026

A bank tested AI customer twins for marketing, with mixed lessons for businesses

Nov 15, 2026

What makes a product vintage, and why the distinction matters to retailers

Nov 15, 2026

EU business social media use rises, but a gap remains by company size

Nov 15, 2026

Why startups may benefit from testing locally before expanding abroad

Nov 14, 2026

Novel product ideas can be harder to try but more rewarding afterward

Nov 14, 2026

What is in an online cart can influence whether shoppers check out

Nov 14, 2026

Subscription plans can miss customers who would save money, Lyft research finds

Nov 14, 2026

Workers with worse shifts than their colleagues were more likely to leave, restaurant study finds

Nov 14, 2026

More product options do not always reach more customers, cosmetics study finds

Nov 14, 2026

EU household spending grew in 2025 as communication purchases led gains

Nov 13, 2026

Ad experiments can help predict which campaigns drive additional sales

Nov 13, 2026

Browser choice screens lifted Firefox usage in Europe, researchers find

Nov 13, 2026

Online product rankings can cut shipping costs without reducing sales, experiment finds

Nov 13, 2026

Large companies lead EU service exports, but smaller firms dominate in some markets

Nov 13, 2026